deltatrials
Completed PHASE3 INTERVENTIONAL 24-arm NCT01763866

LDL-C Assessment With PCSK9 Monoclonal Antibody Inhibition Combined With Statin Therapy-2 (LAPLACE-2)

A Double-blind, Randomized, Placebo and Ezetimibe Controlled, Multicenter Study to Evaluate Safety, Tolerability and Efficacy of AMG 145 on LDL-C in Combination With Statin Therapy in Subjects With Primary Hypercholesterolemia and Mixed Dyslipidemia

Sponsor: Amgen

Conditions Hyperlipidemia
Interventions Atorvastatin Evolocumab Ezetimibe Placebo to Evolocumab Placebo to Ezetimibe Rosuvastatin Simvastatin
Updated 15 times since 2017 Last updated: Nov 4, 2022 Started: Jan 15, 2013 Primary completion: Nov 12, 2013 Completion: Dec 4, 2013
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Hyperlipidemia, this trial is completed. The trial is conducted by Amgen and has accumulated 15 data snapshots since 2013. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Jun 2018 · 16 months · monthly snapshot~Jun 2018 – ~Sep 2018 · 3 months · monthly snapshot~Sep 2018 – ~Nov 2018 · 2 months · monthly snapshot~Nov 2018 – ~Dec 2018 · 30 days · monthly snapshot~Dec 2018 – ~Apr 2019 · 4 months · monthly snapshot~Apr 2019 – ~Jul 2019 · 3 months · monthly snapshot~Jul 2019 – ~Aug 2020 · 13 months · monthly snapshot~Aug 2020 – ~Jan 2021 · 5 months · monthly snapshot~Jan 2021 – ~Feb 2021 · 31 days · monthly snapshot~Feb 2021 – ~Dec 2022 · 22 months · monthly snapshot~Dec 2022 – ~Jul 2024 · 19 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 12 months · monthly snapshot

Change History

15 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE3

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE3

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  4. Dec 2022 — Jul 2024 [monthly]

    Completed PHASE3

  5. Feb 2021 — Dec 2022 [monthly]

    Completed PHASE3

▶ Show 10 earlier versions

  1. Jan 2021 — Feb 2021 [monthly]

    Completed PHASE3

  2. Aug 2020 — Jan 2021 [monthly]

    Completed PHASE3

  3. Jul 2019 — Aug 2020 [monthly]

    Completed PHASE3

  4. Apr 2019 — Jul 2019 [monthly]

    Completed PHASE3

  5. Dec 2018 — Apr 2019 [monthly]

    Completed PHASE3

  6. Nov 2018 — Dec 2018 [monthly]

    Completed PHASE3

  7. Sep 2018 — Nov 2018 [monthly]

    Completed PHASE3

  8. Jun 2018 — Sep 2018 [monthly]

    Completed PHASE3

  9. Feb 2017 — Jun 2018 [monthly]

    Completed PHASE3

  10. Jan 2017 — Feb 2017 [monthly]

    Completed PHASE3

    First recorded

Jan 2013

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Amgen
Data source: Amgen

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Aalborg, Denmark , Alberton, South Africa , AlmerÃ-a, Spain , Almería, Spain , Amsterdam, Netherlands , Ashford, Australia , Atlanta, United States , Auburn, United States , Bad Krozingen, Germany , Baja, Hungary and 204 more locations